Through the Looking Glass: Unraveling the Stage-Shift of Acute Rejection in Renal Allografts

Journal of Clinical Medicine

卷:11

Nicholas Titzler¹  Christopher Chin¹  Jeremy Wong¹  Chih-hung Lai¹  Wanzin Yazar¹  Jeff Stoll¹  Danielle Krieger¹  Minnie M. Sarwal¹  Srinka Ghosh¹  Francisco Dias Lourenco¹  Reuben D. Sarwal¹ 

[1] NephroSant Inc., 1900 Alameda de las Pulgas, San Mateo, CA 94403, USA;

关键词: renal transplant;    acute rejection;    urine;    cell-free DNA;    multi-analyte;    biomarkers;   

DOI  :  10.3390/jcm11040910

来源: DOAJ

【 摘 要 】

Sub-optimal sensitivity and specificity in current allograft monitoring methodologies underscore the need for more accurate and reflexive immunosurveillance to uncover the flux in alloimmunity between allograft health and the onset and progression of rejection. QSant—a urine based multi-analyte diagnostic test—was developed to profile renal transplant health and prognosticate injury, risk of evolution, and resolution of acute rejection. Q-Score—the composite score, across measurements of DNA, protein and metabolic biomarkers in the QSant assay—enables this risk prognostication. The domain of immune quiescence—below a Q-Score threshold of 32—is well established, based on published AUC of 98% for QSant. However, the trajectory of rejection is variable, given that causality is multi-factorial. Injury and subtypes of rejection are captured by the progression of Q-Score. This publication explores the clinical utility of QSant across the alloimmunity gradient of 32–100 for the early diagnosis of allograft injury and rejection.

【 授权许可】

Unknown